UNSPSC 51102846: Erythromycin/sulfisoxazole

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM900. This VA Drug Class (AM900) classifies this compound as belonging to the group ANTI-INFECTIVES, OTHER.

UNSPSC 51102846 Erythromycin/sulfisoxazole is a Commodity code, but the recent state and local opportunities posted under it do not align with this antibiotic-sulfonamide combination. Instead, the code's recent activity spans a divergent set of health and emergency-response procurements: naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, emergency medical and first aid supplies for fire departments, and generic multi-source pharmaceuticals and OTC products through cooperative purchasing. The scope mismatch suggests either mis-tagging in state and local procurement systems or a code classification that does not reflect current buying practice. The issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), municipal fire departments (City of Tampa), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving state and local government facilities across multiple states including Oregon).

Recent opportunities show geographic spread across Florida, Texas, and Minnesota, with multistate cooperative purchasing adding national reach through MMCAP participation. Representative solicitations include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (IFB 60459723LAS, due July 26, 2023); the City of Tampa's IFB for medical and first aid supplies for the Fire Department Rescue Division, 169 line items with an estimated contract value of $700,000.00, designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5% bid discount (26P00145, due March 13, 2026); the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026 (S1070000015802); and the Texas HHS Commission's RFI on direct-to-manufacturer prescriptions to gather vendor capabilities for a potential future Therapeutic Pharmacy Initiative program (HHS0017013, issued April 3, 2026). The code shows little decision-relevant activity aligned with erythromycin/sulfisoxazole procurement specifically, and business development professionals should verify code accuracy before committing pursuit resources.